Synthetic lethality, arises when co‐occurring mutations in two genes kill cells, whereas mutation of either alone is compatible with viability. The concept of synthetic lethality in cancer research, led to the approval of selective sensitivity of Breast Cancer Susceptibility Gene (BRCA)‐mutated cancers to poly (ADP‐ribose) polymerase (PARP) inhibitors.
In order to overcome drug resistance, which results in feedback-mediated activation of parallel signalling pathways, technologies such as RNA interference and CRISPR‐Cas9‐mediated gene knockout have greatly facilitated discovery of drug–drug synthetic lethality. Information from the genetic screens provide potential targets of ‘synthetic lethality’, making compound screens more practical and amenable for treatment suggestions.
Our biologists can actively support drug discovery programs that want to explore screening of FDA‐approved compounds in combination with drugs that are already in clinical use, with poor efficacy, and exploit synergic interactions for a given disease. We have experience advancing projects that employ these strategies, including the use of software and databases with which to accelerate discovery of the best conditions for testing.
To know more about our biology services offering or to request our brochure, please reach out to us at discovery@o2h.com.
